Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.
Humacyte: Revenue Ramp From Symvess Incoming
Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valuation appears reasonable given future growth prospects and insider buying.
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer and Treasurer BJ Scheessele - Chief Commercial Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte's First Quarter Results Conference Call. Currently, all participants are in a listen-only mode.
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
